# A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

> **NCT00159653** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 500 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Xalacom
- **DRUG:** Xalatan
- **DRUG:** Timolol

## Key facts

- **NCT ID:** NCT00159653
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00159653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00159653, "A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00159653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*